NextCure, Inc. Gains 201.83%
NextCure, Inc. (NXTC:NASDAQ) shot up at $6.58, a gain of 201.8%. On Tue, Jul 14, 2026, NXTC:NASDAQ hit a New 2-Week High of $6.58. The stock got featured on our News Catalysts scanner on Tue, Jul 14, 2026 at 02:17 PM in the 'ACQUISITION' category. From Tue, Jun 30, 2026, the stock recorded 55.56% Up Days and 40.00% Green Days
The stock spiked on Tue, Jul 14, 2026 at $9.9 with a volume of 109M+.
About NextCure, Inc. (NXTC:NASDAQ)
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.
Top 10 Gainers:
- NextCure, Inc. (NXTC:NASDAQ), 201.83%
- CN Energy Group. Inc. (CNEY:NASDAQ), 56.35%
- Twin Vee Powercats Co. (VEEE:NASDAQ), 54.91%
- SemiLEDs Corporation (LEDS:NASDAQ), 47.37%
- America's Car-Mart, Inc. (CRMT:NASDAQ), 41.72%
- Shuttle Pharmaceuticals Holdings, Inc. (SHPH:NASDAQ), 40.54%
- UTime Limited (FXHO:NASDAQ), 33.72%
- SK hynix Inc. (SKHY:NASDAQ), 27.29%
- Basel Medical Group Ltd (BMGL:NASDAQ), 26.59%
- Perpetuals.com Ltd Sponsored ADS Repstg Shs (New) (PDC:NASDAQ), 26.48%